412 related articles for article (PubMed ID: 24531792)
1. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.
Gewandter JS; Mohile SG; Heckler CE; Ryan JL; Kirshner JJ; Flynn PJ; Hopkins JO; Morrow GR
Support Care Cancer; 2014 Jul; 22(7):1807-14. PubMed ID: 24531792
[TBL] [Abstract][Full Text] [Related]
2. High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies.
Rossignol J; Cozzi B; Liebaert F; Hatton S; Viallard ML; Hermine O; Greco C
Support Care Cancer; 2019 Aug; 27(8):3053-3059. PubMed ID: 30607681
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.
Barton DL; Wos EJ; Qin R; Mattar BI; Green NB; Lanier KS; Bearden JD; Kugler JW; Hoff KL; Reddy PS; Rowland KM; Riepl M; Christensen B; Loprinzi CL
Support Care Cancer; 2011 Jun; 19(6):833-41. PubMed ID: 20496177
[TBL] [Abstract][Full Text] [Related]
4. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
[TBL] [Abstract][Full Text] [Related]
5. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
6. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Hershman DL; Lacchetti C; Dworkin RH; Lavoie Smith EM; Bleeker J; Cavaletti G; Chauhan C; Gavin P; Lavino A; Lustberg MB; Paice J; Schneider B; Smith ML; Smith T; Terstriep S; Wagner-Johnston N; Bak K; Loprinzi CL;
J Clin Oncol; 2014 Jun; 32(18):1941-67. PubMed ID: 24733808
[TBL] [Abstract][Full Text] [Related]
7. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
[TBL] [Abstract][Full Text] [Related]
8. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.
Gewandter JS; Chaudari J; Ibegbu C; Kitt R; Serventi J; Burke J; Culakova E; Kolb N; Sluka KA; Tejani MA; Mohile NA
Support Care Cancer; 2019 May; 27(5):1765-1774. PubMed ID: 30151681
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.
Ewertz M; Qvortrup C; Eckhoff L
Acta Oncol; 2015 May; 54(5):587-91. PubMed ID: 25751757
[TBL] [Abstract][Full Text] [Related]
10. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
Wong ML; Cooper BA; Paul SM; Abrams G; Topp K; Kober KM; Chesney MA; Mazor M; Schumacher MA; Conley YP; Levine JD; Miaskowski C
Support Care Cancer; 2019 Oct; 27(10):3905-3912. PubMed ID: 30770977
[TBL] [Abstract][Full Text] [Related]
11. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of topical Citrullus colocynthis (bitter apple) extract oil in chemotherapy-induced peripheral neuropathy: A pilot double-blind randomized placebo-controlled clinical trial.
Rostami N; Mosavat SH; Heydarirad G; Arbab Tafti R; Heydari M
Phytother Res; 2019 Oct; 33(10):2685-2691. PubMed ID: 31373112
[TBL] [Abstract][Full Text] [Related]
14. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
[TBL] [Abstract][Full Text] [Related]
15. Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
Chu SH; Lee YJ; Lee ES; Geng Y; Wang XS; Cleeland CS
Support Care Cancer; 2015 Feb; 23(2):513-24. PubMed ID: 25256375
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
Gewandter JS; Kleckner AS; Marshall JH; Brown JS; Curtis LH; Bautista J; Dworkin RH; Kleckner IR; Kolb N; Mohile SG; Mustian KM
Support Care Cancer; 2020 Jun; 28(6):2553-2562. PubMed ID: 31494735
[TBL] [Abstract][Full Text] [Related]
17. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Hershman DL; Unger JM; Crew KD; Minasian LM; Awad D; Moinpour CM; Hansen L; Lew DL; Greenlee H; Fehrenbacher L; Wade JL; Wong SF; Hortobagyi GN; Meyskens FL; Albain KS
J Clin Oncol; 2013 Jul; 31(20):2627-33. PubMed ID: 23733756
[TBL] [Abstract][Full Text] [Related]
18. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Mukai H; Katsumata N; Sunada Y; Watanabe T; Hausheer FH
Support Care Cancer; 2009 Dec; 17(12):1483-91. PubMed ID: 19330359
[TBL] [Abstract][Full Text] [Related]
20. Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.
Ajewole VB; Cox JE; Swan JT; Chikermane SG; Lamoth B; Iso T; Okolo LO; Ford CL; Schneider AM; Hobaugh EC; Baker KR
Support Care Cancer; 2020 Apr; 28(4):1901-1912. PubMed ID: 31359183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]